JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online January 16, 2008, 10.2967/jnumed.107.045641
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.107.045641v1
49/2/195    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fonti, R.
Right arrow Articles by Salvatore, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fonti, R.
Right arrow Articles by Salvatore, M.
Journal of Nuclear Medicine Vol. 49 No. 2 195-200
© 2008 by Society of Nuclear Medicine

doi: 10.2967/jnumed.107.045641

Clinical Investigation

18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma

Rosa Fonti1, Barbara Salvatore2, Mario Quarantelli1, Cesare Sirignano1, Sabrina Segreto3, Fara Petruzziello4, Lucio Catalano4, Raffaele Liuzzi1, Bruno Rotoli4, Silvana Del Vecchio3, Leonardo Pace3 and Marco Salvatore3

1 Istituto di Biostrutture e Bioimmagini-CNR, Napoli, Italy; 2 Fondazione SDN-IRCCS, Naples, Italy; 3 Diagnostic Imaging Department, University Federico II, Naples, Italy; and 4 Hematology Department, University Federico II, Naples, Italy

Correspondence: For correspondence or reprints contact: Rosa Fonti, MD, Istituto di Biostrutture e Bioimmagini-CNR, Via Pansini 5, 80131 Napoli, Italy. E-mail: fontir{at}tin.it

New imaging techniques have been introduced to assess the extent and severity of disease in multiple myeloma (MM) patients. The aim of our study was to compare newer imaging modalities—such as 18F-FDG PET/CT, 99mTc-methoxyisobutylisonitrile (99mTc-MIBI) scintigraphy, and MRI—to assess their relative contribution in the evaluation of MM patients at diagnosis. Methods: Thirty-three newly diagnosed patients with MM were prospectively studied. Diagnosis and staging were made according to standard criteria. All patients underwent whole-body 18F-FDG PET/CT, whole-body 99mTc-MIBI, and MRI of the spine and pelvis within 10 d, and imaging findings were compared. Results: 18F-FDG PET/CT was positive in 32 patients (16 focal uptake, 3 diffuse uptake, 13 focal and diffuse uptake), 99mTc-MIBI was positive in 30 patients (6 focal, 11 diffuse, 13 focal and diffuse uptake), and MRI of the spine and pelvis was positive in 27 patients (6 focal, 13 diffuse, 8 focal and diffuse uptake). 18F-FDG PET/CT showed a total of 196 focal lesions (178 in bones and 18 in soft tissues), of which 121 were in districts other than the spine and pelvis, whereas 99mTc-MIBI visualized 63 focal lesions (60 in bones and 3 in soft tissues), of which 53 were in districts other than the spine and pelvis. In the spinal and pelvic regions, 18F-FDG PET/CT detected 75 focal lesions (35 in spine and 40 in pelvis), 99mTc-MIBI visualized 10 focal lesions (1 in spine and 9 in pelvis), and MRI detected 51 focal lesions (40 in spine and 11 in pelvis). Conclusion: In whole-body analysis, 18F-FDG PET/CT performed better than 99mTc-MIBI in the detection of focal lesions, whereas 99mTc-MIBI was superior in the visualization of diffuse disease. In the spine and pelvis, MRI was comparable to 18F-FDG PET/CT and 99mTc-MIBI in the detection of focal and diffuse disease, respectively. Because myelomatous lesions may often occur out of spinal and pelvic regions, MRI should be reserved to the evaluation of bone marrow involvement of these districts, whereas 18F-FDG PET/CT can significantly contribute to an accurate whole-body evaluation of MM patients. Finally, whole-body 99mTc-MIBI, despite its limited capacity in detecting focal lesions, may be an alternative option when a PET facility is not available.

Key Words: multiple myeloma • 18F-FDG-PET/CT • 99mTc-MIBI • MRI

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  



This article has been cited by other articles:


Home page
RadiologyHome page
Y. Ohno, H. Koyama, Y. Onishi, D. Takenaka, M. Nogami, T. Yoshikawa, S. Matsumoto, Y. Kotani, and K. Sugimura
Non-Small Cell Lung Cancer: Whole-Body MR Examination for M-Stage Assessment--Utility for Whole-Body Diffusion-weighted Imaging Compared with Integrated FDG PET/CT
Radiology, August 1, 2008; 248(2): 643 - 654.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2008 by the Society of Nuclear Medicine.